Pharmacotherapy for social phobia: What works, what might work, and what does not work at all

CNS Spectrums

Volumn 4, Issue 11, 1999, Pages 61-68

  Van Ameringen, Michael ^a   Mancini, Catherine ^a   Farvolden, Peter ^a   Oakman, Jonathan ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BUSPIRONE; CLONAZEPAM; CLONIDINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; ONDANSETRON; PAROXETINE; PHENELZINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

COMORBIDITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW; SOCIAL BEHAVIOR; SOCIAL PHOBIA; TREATMENT INDICATION;

EID: 0032705962     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900012517     Document Type: Review

References (70)

1. Diagnostic and Statistical Manual cf Mental Disorders. 4th ed W àshington DC: American Psychiatric Press; 1994.
2. Kessler RC, McGonagle KA, Zhao S, et ai Lifetime and 12-month prevalence of DS.M-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Cen Pychiatry): 1994alS-19.
3. Schneier FR, Johnson J, Homig CD, et al Social phobia: morbidity and morbidity in an epidemiologic sample. Arch nfiicteu:1992;4ft282-28&
4. Katzelnick DJ, Kobak K. J, Helitad CP, et al The direct and indirect costs of social phobia in managed care patients. Presented at 19th National Conference of the Anxiety Disorders Asaociarkncf America; Jlarch 25-23,1999; San Diego, Calif.
5. Liebowitz MR, German JM, Fyer AJ, et al Social phobia: review of a neglected anxiety disorder. Arch Gen Psychiarty. 1985;42:729-736.
6. Van Ameringen M, Mancini C, Wilson C, et al Hie prevalence of school dropouts in an anxiety disorders chnic. Presented aü 148th Annual Meeting of the American Psychiatric Association; May 24,1995; Miami, Fk
7. Van Ameringen M, Mancini C, Styan G, et al Major depression in patients with social phobia. Am J Psyuiatt): 1990;147:637-639.
8. Robins L, Helyer JE, Weissman MM, et al Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-958.
9. Albano AM. Cognitive-behavioral interventions with socially phobic children. Presented at 5th Internet World Conference on Biomédical Sciences; December 7-16, 1998; Ontario, Canada.
10. Heimberg RG, Jusler HR. Cognitive behavioural treatments: literature renew. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, eds. Social Phobia: Diagnosis Assessment and Treatment. New York, NY: Guilford Press; 1995561-309.
11. Taylor S. Meta-analysis of cognitive-behavioural treatments for social phobia. J Behai- Ther Exp Psychiatr. 199627:1-9.
12. Gelernter CS, Uhde TW, Cimboh'c P, et al. Cognitive- ' behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry: 1991:48:938-945.
13. Liebowitz MR, Schneier P, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled trial. Arch Gen Psychiatry: 1992;49:290-300.
14. van Miel LM, Den Boer JA, Westenberg HGM. Psychophaimacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MOAA inhibitor. Ew KeuropsychopharmacoL 1992221-29.
15. Fahlen T, Nïlsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofanomine: a double-blind placebo-controlled study. Ada Psychiatr ScantL 1995;92:351-358.
16. Lett M, Greist JH, Jeffeison JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, doubleblind study. Join Psychopharmacol 1997;! 7255-260.
17. Versiani M, Nardi AE, Mundion FD, et al. Phaimacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br ] Psychiatry: 1992;161:353-360.
18. Schneier FR, Goetz D, Campeas BF, et al. Placebo controlled trial of moclobemide in social phobia. Br J Psychiatry: 1998;172:70-77.
19. 19. Noyés R, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997;17247-254.
20. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neumsd 1997247:71-80.
21. Stein MB. Medication treatments for panic disorder and social phobia. Depress Anxiety: 1998;7:134-138.
22. Davidson JRT, Potts NS, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423428.
23. van Miel LM, Den Boer J, Westenberg HGM. Psychophaimacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychophamacology: 1994;115:128-134.
24. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine in the treatment of social phobia: a double-blind, placebocontrolled study. Am J Psychiatry. 1999;156:756-760.
25. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am ] Psychiatry. 1995;152:1368-1371.
26. Diagnostic and Statistical Manual of Mental Disorders, 3 ed. Washington, DC: American Psychiatric Association; 1980.
27. Van Ameringen M, Swinson R, Walker JR, Lane RM. A placebo-controlled study of sertraline in generalized social phobia. Presented at 19th National Conference of the Anxiety Disorders Association of America; March 2528,1999; San Diego, Calif.
28. Blomhoff S, Haug TT, Humble M, et al. Treatment of generalized social phobia. Presented at: 152nd Annual Meeting of the American Psychiatric Association; May 20,1999; Washington, DC.
29. Stein M, Liebowitz M, Lydiard B, et al. Paroxetine in the treatment of generalized social phobia (social anxiety disorder). JAMA. 1998;280.708-713.
30. Baldwin D, Bobes j, Stein DJ, Scharwachter I, Faure XI. Paroxetine in social phobia/social anxiety disorder. Er J Psychiatry: 1999-.175:120-126.
31. Allgulander C. Paroxetine in social anxiety disorder a randomized placebo-controlled study. Ada Psychiatr ScamL 1990:100:193-198.
32. Clarke DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry. 1991;148:598-605.
33. Diagnostic and Statistical Manual of Mental Disorders. 3 ed rev. Washington, DC: American Psychiatric Association; 1987.
34. van Yliet LM, den Boer JA, Westenberg HGM, et al. Clinical effects of buspirone in social phobia: a doubleblind placebo-controlled study. J Clin Psychiatry. 1997;58:164-168.
35. Emmanuel NT, Johnson XI, Yillareal G. Imipramine in the treatment of social phobia: a double blind study. Presented aU 36th Annual Xleeting of the American College of Neuropsychopharmacology; December 8-12, 1998; Kamuela, Hawaii.
36. Falloon IR, Lloyd GG, Harpin R. The treatment of social phobia: real-life rehearsal with non-professional therapists.JAen-.Uen Dû. 1981:169:180-184.
37. Turner SX1, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994;62:350-358.
38. Bell J, DeVeaugh-Geiss J. Xlulticenter trial of a 5-HT3 antagonist, ondansetron, in social phobia. Presented at: 33rd Annual Xleeting of the American College of Neuropsychopharmacology; December 12-16,1994; San Juan, Puerto Rico.
39. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. ] Clin Psychopharmacol 1999;19-.341-348.
40. Van Ameringen XI, XIancini C, Oakman J. Nefazodone in the treatment of social phobia. J Clin Psychiatry. 1999;60-.96-100.
41. Worthington JJ Hl, Zucker BG, Calvin SL, Fones CSL, Otto XIW, Pollack XIH. Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998;8:131-133.
42. Emmanuel NP, Czepowicz VC, Ware XIR, et al Venlafaxine in social phobia: a case series, [abstract]. 148th Annual Xleeting of the American Psychiatric Association; Xlay 24, 1995; Miami, Fk Abstract NR373:156.
43. Kelsey JE. Venlafaxine in social phobia. PsychopharmacolBulL 1995;31:767-771.
44. van Vliet DI, Westenberg HGXI, van Xlegen HJGX1. Clinical effects of Venlafaxine in social phobia. Presented at: llth Congress of the European College of Neuropsychopharmacology (ECNP); October 31November4,1998; Paris, France.
45. Altamura AC, Pioli R, Vitto XI, XIannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-respnders. Int Clin Psychopharmacol. 1999;14:23945.
46. Emmanuel NP, Lydiard RB, Ballenger JC. Treatment of social phobia with bupropion (letter). J Clin Psychopharmacol 1991;ll:276-277.
47. Simpson HB, Schneier FR, Xlarshall RD, et al. Low dose selegiline (L-deprenyl) in social phobia. Depress Anxiety. 1998:7:126-129.
48. Goldstein S. Treatment of social phobia with clonidine. Bid Psychiatry. 1987 2:369-372.
49. Nardi AE, Xlendlowicz XI, Figueira I, Versiani XI. Valproic acid in social phobia-an open trial. Presented at 6th World Congress of Biological Psychiatr)-; June 22-27, 1999; Nice, France.
50. Albano AM, Di Bartolo PM, Heimberg RG, et al. Children and adolescents: assessment and treatment. In; Heimberg RG, Liebowitz MR, Hope DA, et al, eds. Social Phobia: Diagnosis, Assessment, and Treatment. N'ew York, NT: Guilford Press; 1992.
51. Christoff KA, Scott WON, Kelley ML, et al. Social skills and social problem-solving training for shy young adolescents. Behw Ther. 1985;16:468477.
52. Franco DP, Christoff KA, Crimmins DE, et al. Social skills training for an extremely shy young adolescent: an empirical case study. Behav Ther. 1983;14:568-575.
53. Simeon JG, Ferguson HB. Alprazolam effects in children with anxiety disorders. Can J Psychiatry: 1987 2:570-574.
54. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Washington, DC: American Psychiatric Association; 1994.
55. Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatr): 19923129-33.
56. Kutcher SP, Reiter S, Gardner DM, Klein RG. The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin Korth Am. 1992;15:41-67.
57. Bernstein GA, Borchardt CM, Penrein AR. Anxiety disorders in children and adolescents: a review of the past ten years. ] Am Acad Child Adolesc Psychiatr): 1996;35:1110-1119.
58. Ryan ND, Puig-Antich J. Pharmacological treatment of adolescent psychiatric disorders. ] Adolesc Health Care. 1987;8:137-142.
59. Popper CW. Psychopharmacologic treatment of anxiety disorders in adolescents and children. J Clin Psychiatr): 1993;54:52-63.
60. Manassis K, Bradley S. Fluoxetine in anxiety disorders (letter). }Am Acad Child Adolesc Psychiatry. 1994; 33:761-762.
61. Birmaher B, Waterman GS, Ryan N, et al. Fluoxetine for childhood anxiety disorders. ] Am Acad Child Adolesc Psychiatr): 1994;33.-993-999.
62. Black B, Uhde TW. Elective mutism as a variant of social phobia. }Am Acad Child Adolesc Psychiatry: 1990;31:1090-1094.
63. Golwyn H, Weinstock RC. Phenelzine treatment of elective mutism. 7 Clin Psychiatry: 1990;51:384-385.
64. Black B, Uhde T. Treatment of elective mutism with fluoxetine: a double-blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry. 1994;33:1000-1006.
65. Mancini C, Van Ameringen M, Oakman J, Farvolden P. Serotonergic agents in the treatment of social phobia in children and adolescents: a case series. Depress Anxiety. 1999;10:33-39.
66. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder, a multicenter randomized controlled trial. J.4.V.-L 1998:280:1752-1756.
67. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia: renew of a neglected anxiety disorder. Arch Gen Psychiatry: 1985;42:729-735.
68. Connor KM, Davidson JRT, Potts NLS, et al. Discontinuation of clonazepam in the treatment of social phobia. JClin-PsychophamacoL 1998;18:373-378.
69. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. JClinPsydwpharmacoL 1996;16:218-222.
70. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of sélective serotonin reuptake inhibitors (SSRIs)in social fMia.J Affect Disord. 1996:39:115-121.